TGDD: A Genomics-Based Database for Tumor Treatment Drugs
DOI:
https://doi.org/10.71373/UYBT8671Keywords:
TGDD, cancer genomics, precision medicine, driver mutations, therapeutic drugsAbstract
With advancements in cancer genomics, precision medicine is increasingly being applied in cancer treatment. However, the fragmentation of genetic mutation-related information and the lack of standardized interpretation tools present significant challenges to its effective implementation and clinical decision-making. To address these challenges, we have developed the Tumor Genomic Drug Database (TGDD), a comprehensive genomics-based cancer drug treatment resource. It integrates data on genes, molecular characteristics, cancer types, and therapeutic drugs from established cancer knowledge bases such as CIViC, COSMIC, and OncoKB, providing a unified and standardized clinical support tool. Currently, it encompasses 19,557 entries, including 391 gene datasets, 525 cancer types, 5,322 drug combinations, and 8,109 mutation coordinates. This resource assists clinicians in formulating personalized treatment plans and supports cancer research and drug development.